CONFIDENTIAL MEDICAL CASE REPORT Subject ID: T-0347 Date of Admission: January 3, 2025 Treatment Protocol: Gen-Adapt Pill Series (Experimental Hormonal-Neuroadaptive Therapy) Supervising Physician: Dr. L. M. Harrow, MD, PhD Facility: Novagen Institute for Endocrine and Identity Research
I. SUBJECT PROFILE
Name: Withheld (per privacy protocol)
Age: 36
Sex at Intake: Male
Gender Identity at Intake: Undisclosed
Medical History: Unremarkable. No prior hormone therapy. No psychiatric diagnoses.
Consent Status: Fully informed, signed waiver for experimental protocol.
II. TREATMENT OVERVIEW
The Gen-Adapt Pill Series is designed to induce gradual, systemic feminization through a combination of hormonal modulation, neuroplasticity enhancement, and targeted epigenetic reprogramming. The subject was administered a daily oral dose, monitored weekly for physiological and psychological changes.
III. OBSERVATIONAL TIMELINE
Week 1–2: Initial Response
Physical: Minor skin softening noted. Sebaceous activity reduced. Subject reported increased sensitivity to temperature and touch.
Mental: Mild emotional lability. Subject described dreams involving unfamiliar female personas. No distress reported.
Week 3–4: Hormonal Shift
Physical: Breast tissue began forming (Tanner Stage II). Fat redistribution observed—hips and thighs showed early rounding. Facial hair growth slowed significantly.
Mental: Subject reported heightened empathy and introspection. Expressed interest in journaling and self-reflection. Language use subtly shifted toward more expressive phrasing.
Week 5–8: Intermediate Transition
Physical: Voice pitch elevated by ~20 Hz. Waistline narrowed; muscle mass decreased in upper body. Genital shrinkage noted, with early signs of reconfiguration.
Mental: Subject began referring to self with feminine pronouns. Expressed comfort and curiosity about emerging identity. Emotional range broadened—tears during films, spontaneous laughter, deeper social engagement.
Week 9–12: Advanced Feminization
Physical: Breast development reached Tanner Stage IV. Pelvic tilt and posture adjusted to typical female alignment. Genital transformation progressed toward neovaginal formation (non-surgical).
Mental: Subject adopted new name (withheld). Reported sense of “mental clarity” and “emotional authenticity.” Interests shifted toward aesthetic expression, interpersonal connection, and nurturing roles.
Week 13–16: Final Integration
Physical: Full external female phenotype achieved. Skin tone evened, hair texture softened. Menstrual simulation cycle initiated via hormonal rhythm.
Mental: Subject identified fully as female in all contexts. Psychological evaluations confirmed stable mood, high self-esteem, and congruent gender identity. No signs of dysphoria or cognitive dissonance.
IV. OUTCOME & RECOMMENDATIONS
Subject T-0347 completed the Gen-Adapt protocol with full physiological and psychological integration into a female identity. No adverse effects were recorded. Subject declined reversal options and requested permanent documentation of her transition.
Recommended Follow-Up:
Quarterly endocrine checkups
Optional voice therapy (declined)
Supportive counseling (ongoing, voluntary)
Signed: Dr. L. M. Harrow, MD, PhD Lead Researcher, Novagen Institute Date: May 1, 2025
CONFIDENTIAL MEDICAL CASE REPORT – FOLLOW-UP Subject ID: T-0347 Date of Evaluation: November 3, 2025 Treatment Protocol: Gen-Adapt Pill Series (Completed May 2025) Supervising Physician: Dr. L. M. Harrow, MD, PhD Facility: Novagen Institute for Endocrine and Identity Research
I. SUBJECT STATUS – SIX MONTHS POST-TREATMENT
Current Gender Identity: Female (self-affirmed)
Physical Status: Stable, fully feminized phenotype
Mental Health: Positive adaptation, no signs of dysphoria or post-treatment distress
Lifestyle Integration: Independent living, employed part-time, socially active
II. OBSERVATIONAL SUMMARY
A. Physical Health
Subject maintains a healthy BMI (21.4), with stable hormone levels consistent with cisgender female ranges.
Menstrual simulation cycles continue regularly, with no reported discomfort.
Secondary sexual characteristics (breast tissue, fat distribution, skin texture) remain consistent and well-developed.
Subject reports satisfaction with physical appearance and bodily function.
B. Psychological Adaptation
Subject demonstrates high emotional resilience and self-awareness.
Expresses strong sense of identity congruence and personal authenticity.
Language and behavior align with affirmed gender identity; no regression or confusion noted.
Participates in community support groups and creative workshops.
C. Social & Sexual Functioning
Subject reports engaging in consensual romantic and sexual relationships.
Describes experiences as affirming and emotionally connective.
No signs of sexual dysfunction or discomfort; libido within normal range.
Subject has declined further clinical intervention, stating “I feel whole.”
III. CLINICAL NOTES
Subject’s transition is considered medically and psychologically successful.
No adverse effects from Gen-Adapt protocol have emerged.
Subject has requested documentation for legal gender marker update and is pursuing long-term wellness independently.
Follow-up sessions now optional; subject attends quarterly check-ins voluntarily.
Signed: Dr. L. M. Harrow, MD, PhD Lead Researcher, Novagen Institute Date: November 3, 2025
Comentarios
Publicar un comentario